Back

CARDIO-TTRansform: efficacy and safety of eplontersen in patients with transthyretin amyloid cardiomyopathy

28 August 2026 (11:00 - 11:10)
Organised by: Logo
Congress Presentation Part of: HOT LINE 1 Infiltrative Myocardial Disease ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Mathew Maurer

Columbia University Irving Medical Centre, New York (United States of America)

14 More presentations in this session

Presentation thumbnail
Discussant review - CARDIO-TTRansform
Professor G. Sinagra (Trieste, IT)
Slides Video
Presentation thumbnail
Panel discussion - CARDIO-TTRansform
Presentation thumbnail
SINGLE-AF: Anticoagulation for atrial fibrillation with intermediate stroke risk
Professor B. Joung (Seoul, KR)
Slides Video
Presentation thumbnail
Discussant review - SINGLE-AF
Professor I. Van Gelder (Groningen, NL)
Slides Video
Presentation thumbnail
Panel discussion - SINGLE-AF

Access the full session

Session thumbnail
HOT LINE 1
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 11:00 CET
You may be interested in
thumbnail
Congress Presentation
CARDIO-TTRansform trial in ATTR-CM: design and baseline characteristics
9 May 2026
thumbnail
Congress Presentation
RNA interference therapy in transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials
31 August 2025
thumbnail
Congress Presentation
Tolerability of continued treatment with ATTR depleter ALXN2220 in the open-label extension of Phase 1 study NI006-101
31 August 2025
thumbnail
Congress Presentation
HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources